Our lead drug candidate, CNM-Au8, is an oral suspension of clean-surfaced, catalytically-active gold nanocrystals. Resulting from a number of patented manufacturing breakthroughs, CNM-Au8 is currently in development as a disease-modifying treatment for Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson’s Disease. There have been over 350 patient years of CNM-Au8 exposure without identified safety signals.
1Camandola, S. & Mattson, M. P. Brain metabolism in health, aging, and neurodegeneration. EMBO J 36, 1474–1492 (2017).